Cincinnati Epilepsy Center Again Designated Level 4
The Epilepsy Center at the UC Neuroscience Institute has again been designated a Level 4 Epilepsy Centerthe highest levelby the National Association of Epilepsy Centers (NAEC). The center, directed by Michael Privitera, MD, a professor in the UC College of Medicines Department of Neurology and Rehabilitation Medicine, has held this designation consistently since 2005.
The NAEC is a nonprofit trade association with a membership of more than 170 epilepsy centers. The organization defines Level 4 epilepsy centers as "having the professional expertise and facilities to provide the highest level medical and surgical evaluation and treatment of patients with complex epilepsy. The designation of Level 4 or the NAECs other level, Level 3, is made as a result of member centers responses to a self-designation survey.
The UC Neuroscience Institute is one of four institutes of the UC College of Medicine and UC Health. It includes 14 centers and programs.
Related Stories
UC expert weighs in on current MASH treatment approaches
June 5, 2026
As MedCentral recently reported, pending broader pharmacologic approvals for metabolic dysfunction-associated steatohepatitis (MASH), lifestyle modifications remain the go-to intervention.
At least two weather patterns increase headaches, UC study suggests
June 4, 2026
University of Cincinnati physicians and collaborators identified two specific weather patterns that increase headache and migraine risk and found the preventive medication fremanezumab (Ajovy) can reduce weather‑associated headaches. The findings will be presented at the American Headache Society Annual Scientific Meeting in Orlando.
UC researcher secures $3.3M grant to study microplastics’ impact on heart
June 2, 2026
The National Institute of Environmental Health Sciences awarded a $3.3M grant to University of Cincinnati researcher Hong‑Sheng Wang, PhD, to study how microplastics and nanoplastics affect cardiovascular health.